BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Pickett JL, Chou A, Andrici JA, Clarkson A, Sioson L, Sheen A, Reagh J, Najdawi F, Kim Y, Riley D, Maidens J, Nevell D, McIlroy K, Valmadre S, Gard G, Hogg R, Turchini J, Robertson G, Friedlander M, Gill AJ. Inflammatory Myofibroblastic Tumors of the Female Genital Tract Are Under-recognized: A Low Threshold for ALK Immunohistochemistry Is Required. Am J Surg Pathol 2017;41:1433-42. [PMID: 28731868 DOI: 10.1097/PAS.0000000000000909] [Cited by in Crossref: 37] [Cited by in F6Publishing: 40] [Article Influence: 6.2] [Reference Citation Analysis]
Number Citing Articles
1 Zhang L, Luan L, Shen L, Xue R, Huang J, Su J, Huang Y, Xu Y, Wang X, Shao Y, Ji Y, Xu C, Hou Y. Uterine inflammatory myofibroblastic tumor harboring novel NUDCD3-ROS1 and NRP2-ALK fusions: clinicopathologic features of 4 cases and literature review. Virchows Arch 2023;482:567-80. [PMID: 36624188 DOI: 10.1007/s00428-022-03457-7] [Reference Citation Analysis]
2 Devins KM, Samore W, Nielsen GP, Deshpande V, Oliva E. Leiomyoma-like Morphology in Metastatic Uterine Inflammatory Myofibroblastic Tumors. Mod Pathol 2023;36:100143. [PMID: 36806735 DOI: 10.1016/j.modpat.2023.100143] [Reference Citation Analysis]
3 Ladwig NR, Bean GR, Pekmezci M, Boscardin J, Joseph NM, Therrien N, Sangoi AR, Piening B, Rajamanickam V, Galvin M, Bernard B, Zaloudek C, Rabban JT, Garg K, Umetsu SE. Uterine Inflammatory Myofibroblastic Tumors: Proposed Risk Stratification Model Using Integrated Clinicopathologic and Molecular Analysis. Am J Surg Pathol 2023;47:157-71. [PMID: 36344483 DOI: 10.1097/PAS.0000000000001987] [Reference Citation Analysis]
4 Karpathiou G, Devouassoux-Shisheboran M, Stolnicu S, Chauleur C, Péoc'h M. Uterine inflammatory myofibroblastic tumor. Pathol Res Pract 2023;242:154335. [PMID: 36706588 DOI: 10.1016/j.prp.2023.154335] [Reference Citation Analysis]
5 Horwood G, Busca A, Singh S. Fertility-preserving management of an inflammatory myofibroblastic tumor: A case report and review of the literature. Case Rep Womens Health 2023;37:e00481. [PMID: 36798099 DOI: 10.1016/j.crwh.2023.e00481] [Reference Citation Analysis]
6 Bowman CJ, Medeiros F, Fadare O, Sangoi AR, Horvai AE, Devine WP, McCluggage WG, Rabban JT. ALK Immunoexpression is Specific for Inflammatory Myofibroblastic Tumor Among Vulvovaginal Mesenchymal Neoplasms. Int J Gynecol Pathol 2023;42:1-10. [PMID: 35180768 DOI: 10.1097/PGP.0000000000000858] [Reference Citation Analysis]
7 Tang F, Dai G, Huang X, Wang D. Uterine inflammatory myofibroblastic tumor presented as abnormal uterine bleeding: Two cases report and literature review. Medicine (Baltimore) 2022;101:e32141. [PMID: 36550868 DOI: 10.1097/MD.0000000000032141] [Reference Citation Analysis]
8 Chang B, Wang Z, Ren M, Yao Q, Zhao L, Zhou X. A Novel CASC15-ALK and TFG-ROS1 Fusion Observed in Uterine Inflammatory Myofibroblastic Tumor. Int J Gynecol Pathol 2022. [PMID: 36730016 DOI: 10.1097/PGP.0000000000000926] [Reference Citation Analysis]
9 Senthilnayagam B, Manjani S, Preethi S, Subrajaa KK. Inflammatory Myofibroblastic Tumor of the Uterus: An Under-recognized Entity—A Case Report and Literature Review. Journal of South Asian Federation of Obstetrics and Gynaecology 2022;14:621-622. [DOI: 10.5005/jp-journals-10006-2128] [Reference Citation Analysis]
10 Croce S, Devouassoux-Shisheboran M, Pautier P, Ray-Coquard I, Treilleux I, Neuville A, Arnould L, Just PA, Belda MALF, Averous G, Leroux A, Mery E, Loussouarn D, Weinbreck N, Le Guellec S, Mishellany F, Morice P, Guyon F, Genestie C. Uterine sarcomas and rare uterine mesenchymal tumors with malignant potential. Diagnostic guidelines of the French Sarcoma Group and the Rare Gynecological Tumors Group. Gynecol Oncol 2022:S0090-8258(22)00515-7. [PMID: 36114030 DOI: 10.1016/j.ygyno.2022.07.031] [Reference Citation Analysis]
11 Schwartz C, Gundogan F, Singh K, Schoolmeester JK, Banet N. Inflammatory Myofibroblastic Tumor of the Placenta With Subsequent Successful Pregnancy and Benign Hysterectomy: A Case Report With 59-Month Follow-up. Int J Gynecol Pathol 2022. [PMID: 35838599 DOI: 10.1097/PGP.0000000000000893] [Reference Citation Analysis]
12 Watkins JC, Roberts DJ. Placenta-associated uterine inflammatory myofibroblastic tumor with a novel FBLN1-ALK1 fusion. Human Pathology Reports 2022;28:300647. [DOI: 10.1016/j.hpr.2022.300647] [Reference Citation Analysis]
13 Kanatani Y, Ogawa K, Shinkuma S, Mitsui Y, Miyagawa F, Ando J, Kuwahara M, Takeda M, Fujii T, Fukumoto T, Hirose T, Asada H. An unusual case of inflammatory myofibroblastic tumor harboring ALK-CARS fusion with few inflammatory cells: A potential diagnostic pitfall. J Dermatol 2022. [PMID: 35616148 DOI: 10.1111/1346-8138.16472] [Reference Citation Analysis]
14 Kertowidjojo EC, Bennett JA. Update on Uterine Mesenchymal Neoplasms. Surgical Pathology Clinics 2022. [DOI: 10.1016/j.path.2022.02.008] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
15 Kuisma H, Jokinen V, Pasanen A, Heikinheimo O, Karhu A, Välimäki N, Aaltonen L, Bützow R. Histopathologic and Molecular Characterization of Uterine Leiomyoma–like Inflammatory Myofibroblastic Tumor: Comparison to Molecular Subtypes of Uterine Leiomyoma. American Journal of Surgical Pathology 2022;Publish Ahead of Print. [DOI: 10.1097/pas.0000000000001904] [Reference Citation Analysis]
16 Ng ZY, Khaing CT, Aggarwal I. Inflammatory myofibroblastic tumor: an under recognized differential of uterine mesenchymal tumors. Int J Gynecol Cancer 2022;32:212-3. [DOI: 10.1136/ijgc-2021-003247] [Reference Citation Analysis]
17 张 艳. A Case of Uterine Inflammatory Myofibroblastic Tumor. ACM 2022;12:4978-4982. [DOI: 10.12677/acm.2022.126721] [Reference Citation Analysis]
18 Chiang S. Mesenchymal Tumors, Pathology of the Uterine Corpus. Encyclopedia of Pathology 2022. [DOI: 10.1007/978-3-319-28845-1_5626-1] [Reference Citation Analysis]
19 López de Sa A, Pascual A, Garcia Santos J, Mendez R, Bellon M, Ramirez M, Matute F, Del Arco C, Manzano A, Coronado P, Casado A, Marquina G. Inflammatory myofibroblastic tumour of an unusual presentation in the uterine cervix: a case report. World J Surg Oncol 2021;19:331. [PMID: 34801049 DOI: 10.1186/s12957-021-02438-5] [Reference Citation Analysis]
20 Sanaya SZ, Matsneva IA, Redkina NA, Telezhnikova IM, Magnaeva AS, Tregubova AV, Asaturova AV, Kometova VV. [Immunohistochemical and molecular diagnosis of inflammatory myofibroblastic tumor of the uterus: a literature review and a clinical case]. Arkh Patol 2021;83:43-8. [PMID: 34609804 DOI: 10.17116/patol20218305143] [Reference Citation Analysis]
21 Gao Y, Shang Q, Wei J, Chen T. The correlation between vaginal microecological dysbiosis-related diseases and preterm birth: A review. Medicine in Microecology 2021;8:100043. [DOI: 10.1016/j.medmic.2021.100043] [Reference Citation Analysis]
22 Walsh EM, Xing D, Lippitt MH, Fader AN, Wethington SL, Meyer CF, Gaillard SL. Molecular Tumor Board Guides Successful Treatment of a Rare, Locally Aggressive, Uterine Mesenchymal Neoplasm. JCO Precis Oncol 2021;5:PO. [PMID: 34250413 DOI: 10.1200/PO.20.00189] [Reference Citation Analysis]
23 Zhang C, Wang Z, Zhuang R, Guo X, Feng Y, Shen F, Liu W, Zhang Y, Tong H, Sun W, Liu J, Wang G, Dai C, Lu W, Zhou Y. Efficacy and Resistance of ALK Inhibitors in Two Inflammatory Myofibroblastic Tumor Patients with ALK Fusions Assessed by Whole Exome and RNA Sequencing. Onco Targets Ther 2020;13:10335-42. [PMID: 33116613 DOI: 10.2147/OTT.S270481] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
24 Chopra S, Lazar AJ, Wang W. Are ALK rearrangements found in smooth muscle tumours of the gastrointestinal tract? Histopathology 2020;76:627-628. [DOI: 10.1111/his.14013] [Reference Citation Analysis]
25 Chiang S, Samore W, Zhang L, Sung YS, Turashvili G, Murali R, Soslow RA, Hensley ML, Swanson D, Dickson BC, Stewart CJR, Oliva E, Antonescu CR. PGR Gene Fusions Identify a Molecular Subset of Uterine Epithelioid Leiomyosarcoma With Rhabdoid Features. Am J Surg Pathol 2019;43:810-8. [PMID: 30829727 DOI: 10.1097/PAS.0000000000001239] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 6.7] [Reference Citation Analysis]
26 Arias-Stella JA 3rd, Benayed R, Oliva E, Young RH, Hoang LN, Lee CH, Jungbluth AA, Frosina D, Soslow RA, Antonescu CR, Ladanyi M, Chiang S. Novel PLAG1 Gene Rearrangement Distinguishes a Subset of Uterine Myxoid Leiomyosarcoma From Other Uterine Myxoid Mesenchymal Tumors. Am J Surg Pathol 2019;43:382-8. [PMID: 30489320 DOI: 10.1097/PAS.0000000000001196] [Cited by in Crossref: 33] [Cited by in F6Publishing: 23] [Article Influence: 11.0] [Reference Citation Analysis]
27 Dvorská D, Škovierová H, Braný D, Halašová E, Danková Z. Liquid Biopsy as a Tool for Differentiation of Leiomyomas and Sarcomas of Corpus Uteri. Int J Mol Sci 2019;20:E3825. [PMID: 31387281 DOI: 10.3390/ijms20153825] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
28 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. In: Kurman RJ, Hedrick Ellenson L, Ronnett BM, editors. Blaustein's Pathology of the Female Genital Tract. Cham: Springer International Publishing; 2019. pp. 535-647. [DOI: 10.1007/978-3-319-46334-6_10] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
29 Ogata M, Hatachi Y, Ogata T, Satake H, Imai Y, Yasui H. Effectiveness of Crizotinib for Inflammatory Myofibroblastic Tumor with ALK mutation. Intern Med 2019;58:1029-32. [PMID: 30449794 DOI: 10.2169/internalmedicine.1640-18] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 2.4] [Reference Citation Analysis]
30 Oliva E, Zaloudek CJ, Soslow RA. Mesenchymal Tumors of the Uterus. Blaustein's Pathology of the Female Genital Tract 2018. [DOI: 10.1007/978-1-4614-3165-7_10-2] [Reference Citation Analysis]